Atrial Fibrillation
Atrial fibrillation (AF or Afib) is the most common cardiac arrhythmia affecting millions worldwide. AF causes the left atrium to fibrillate leading to blood clot formation and increased risk of stroke.
20%-30% of all strokes occur in AF patients
The lifetime risk of getting AF is 1 in 4
Atrial Fibrillation
Therapy Today
(Catheter Ablation)
AF may be treated with medication, cardioversion or with catheter ablation which is considered the golden standard interventional procedure. In catheter ablation procedures lesions are formed in the left atrium around the pulmonary veins where the irregular electrical signals are coming from. Lesions are created with catheters that deliver uniform energy via direct contact with the tissue leading to its destruction and therefore, blockage of the irregular electrical.
The Problem
Existing solutions difficult to use
Up to 40% of patients require 2nd procedure
Tissue contact
is mandatory
No tissue thickness measurement
No lesion monitoring
The Solution
No-Contact Guided Ablation
The first product that allows:
Contactless ablation
Automatic power titration based on tissue thickness
Real-time lesion monitoring
AF Catheter Ablation – Market Opportunity
$58B
Existing Market potential
46.1 Millions
Patients worldwide
>14.2%
CAGR 2019-2025
70% Increase
In diagnosed patients by 2030
>2 Millions
newly diagnosed per year in the US & EU alone
>950k
Procedures/year 2018
>$6.5bn
Market 2025
>$3.5B
M&A Since 2008